GlassScriptPhysician profile
Nidhi Narayan
NPI 1609073386
$13,409.64
in general payments reported to CMS, 2019-2025
58 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,329 · 2020: $1,964 · 2021: $2,220 · 2022: $1,773 · 2023: $1,846 · 2024: $1,504 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,123.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,792.37 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,793.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,524.08 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $1,029.21 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $605.07 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.28 | 2019-2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $515.87 | 2020-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $502.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $466.62 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Abbvie INC. | $293.21 | 2019-2024 | |
| Medtronic, INC. | $276.37 | 2022-2025 | Symplicity G3, Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $260.94 | 2022-2025 | |
| Glaxosmithkline, LLC. | $257.83 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Mannkind Corporation | $240.31 | 2019-2024 | |
| Shire North American Group INC | $192.45 | 2019 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidhi Narayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.